Chenonceaux, France
Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer
Randomised Phase II Study Evaluating Trifluridine/Tipiracil Plus Oxaliplatin ± Nivolumab Versus FOLFOX ± Nivolumab in Patients With HER2 Negative Locally Advanced, Recurrent or Metastatic Gastric, Oesophageal or Oesogastric Junction Adenocarcinoma
Phase
2Span
189 weeksSponsor
UNICANCERCoudekerque-Branche
Recruiting
Evaluation of the Impact of Taking American Ginseng for 8 Weeks on Fatigue in Patients Treated for Localized Breast or Gynecological Cancer
Phase
N/ASpan
262 weeksSponsor
Centre Francois BaclesseCoudekerque-Branche
Recruiting
Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate
Phase
2Span
182 weeksSponsor
Federation Francophone de Cancerologie DigestiveCoudekerque-Branche
Recruiting
Discovery of Microbiome-based Biomarkers for Patients With Cancer Using Metagenomic Approach
Phase
N/ASpan
363 weeksSponsor
Gustave Roussy, Cancer Campus, Grand ParisCoudekerque-Branche
Recruiting
Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment
Phase
N/ASpan
162 weeksSponsor
UNICANCERDunkerque
Recruiting
OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia
Phase
N/ASpan
70 weeksSponsor
French Innovative Leukemia OrganisationDunkerque
Recruiting
Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France
The ASSURE-3 study is a national, multicentric, non-interventional, prospective study in real-life conditions with primary data collection in adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) previously treated with two or more Tyrosine Kinase Inhibitors (TKIs). It will be conducted in France with hematologists, onco-hematologists, physicians with documented involvement in managing Ph+ CML-CP patients in routine practice, practicing in public or private health care institutions. Each patient will be followed during 15 months at M0, M1 and then every 3 months (rhythm of visits according to the routine clinical care), or until premature discontinuation of asciminib treatment. Historical data will be abstracted retrospectively by the participating physicians from patient files, to collect information using an electronic case report form (eCRF). Primary data will be collected during inclusion and follow-up visits
Phase
N/ASpan
145 weeksSponsor
Novartis PharmaceuticalsDunkerque
Recruiting
Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients
Phase
N/ASpan
159 weeksSponsor
Intergroupe Francophone du MyelomeDunkerque
Recruiting
6-month Efficacy and Safety of Synolis VA 80/160 in Hip Osteoarthritis
Phase
N/ASpan
110 weeksSponsor
Aptissen SADunkerque
Recruiting
Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France
Included patients will be followed until the end of study, death or lost to follow-up even if ribociclib and ET are discontinued. The end of the study is defined as 3 years after the first visit of the last patient included (Last Patient First Visit [LPFV]). The total duration of the study will be 4 years and half (18 months of inclusion + 3 years of follow-up). Thus, a patient included at the beginning of the inclusion period will be followed for 4 years and half and a patient included at the end of the inclusion period will be followed for at least 3 years.
Phase
N/ASpan
290 weeksSponsor
Novartis PharmaceuticalsDunkerque
Recruiting